These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38861913)

  • 1. Synthesis, molecular modeling simulations and anticancer activity of some new Imidazo[2,1-b]thiazole analogues as EGFR/HER2 and DHFR inhibitors.
    Moharram EA; El-Sayed SM; Ghabbour HA; El-Subbagh HI
    Bioorg Chem; 2024 Sep; 150():107538. PubMed ID: 38861913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New thiazole-based derivatives as EGFR/HER2 and DHFR inhibitors: Synthesis, molecular modeling simulations and anticancer activity.
    Sabry MA; Ghaly MA; Maarouf AR; El-Subbagh HI
    Eur J Med Chem; 2022 Nov; 241():114661. PubMed ID: 35964425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3-Methyl-imidazo[2,1-b]thiazole derivatives as a new class of antifolates: Synthesis, in vitro/in vivo bio-evaluation and molecular modeling simulations.
    Ewida MA; Ewida HA; Ahmed MS; Allam HA; ElBagary RI; George RF; Georgey HH; El-Subbagh HI
    Bioorg Chem; 2021 Oct; 115():105205. PubMed ID: 34329992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and in vitro antitumor evaluation of new thieno[2,3-d]pyrimidine derivatives as EGFR and DHFR inhibitors.
    Fouad MM; Ghabbour HA; Shehata IA; El-Ashmawy MB
    Bioorg Chem; 2024 Jul; 148():107401. PubMed ID: 38749115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors.
    Sever B; Altıntop MD; Radwan MO; Özdemir A; Otsuka M; Fujita M; Ciftci HI
    Eur J Med Chem; 2019 Nov; 182():111648. PubMed ID: 31493743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New quinazolinone-based derivatives as DHFR/EGFR-TK inhibitors: Synthesis, molecular modeling simulations, and anticancer activity.
    El-Gazzar YI; Ghaiad HR; El Kerdawy AM; George RF; Georgey HH; Youssef KM; El-Subbagh HI
    Arch Pharm (Weinheim); 2023 Jan; 356(1):e2200417. PubMed ID: 36257809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imidazo[2',1':2,3]thiazolo[4,5-d]pyridazinone as a new scaffold of DHFR inhibitors: Synthesis, biological evaluation and molecular modeling study.
    Ewida MA; Abou El Ella DA; Lasheen DS; Ewida HA; El-Gazzar YI; El-Subbagh HI
    Bioorg Chem; 2018 Oct; 80():11-23. PubMed ID: 29864684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanomolar potency of imidazo[2,1-b]thiazole analogs as indoleamine 2,3-dioxygenase inhibitors.
    Ewida MA; Ewida HA; Ahmed MS; Allam HA; ElBagary RI; George RF; Georgey HH; El-Subbagh HI
    Arch Pharm (Weinheim); 2021 Nov; 354(11):e2100202. PubMed ID: 34313342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thiazolo[4,5-d]pyridazine analogues as a new class of dihydrofolate reductase (DHFR) inhibitors: Synthesis, biological evaluation and molecular modeling study.
    Ewida MA; Abou El Ella DA; Lasheen DS; Ewida HA; El-Gazzar YI; El-Subbagh HI
    Bioorg Chem; 2017 Oct; 74():228-237. PubMed ID: 28865294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel imidazo[2,1-b]thiazoles and imidazo[1,2-a]pyridines tethered with indolinone motif as VEGFR-2 inhibitors and apoptotic inducers: Design, synthesis and biological evaluations.
    Elkotamy MS; Elgohary MK; Al-Rashood ST; Almahli H; Eldehna WM; Abdel-Aziz HA
    Bioorg Chem; 2024 Oct; 151():107644. PubMed ID: 39079394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of a new series of imidazothiazole-hydrazone hybrids as dual EGFR and Akt inhibitors for NSCLC therapy.
    Altıntop MD; Ertorun İ; Akalın Çiftçi G; Özdemir A
    Eur J Med Chem; 2024 Oct; 276():116698. PubMed ID: 39047611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, biological evaluation and molecular modeling study of new (1,2,4-triazole or 1,3,4-thiadiazole)-methylthio-derivatives of quinazolin-4(3H)-one as DHFR inhibitors.
    El-Gazzar YI; Georgey HH; El-Messery SM; Ewida HA; Hassan GS; Raafat MM; Ewida MA; El-Subbagh HI
    Bioorg Chem; 2017 Jun; 72():282-292. PubMed ID: 28499189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New 2-alkoxycyanopyridine derivatives as inhibitors of EGFR, HER2, and DHFR: Synthesis, anticancer evaluation, and molecular modeling studies.
    Hawas SS; El-Sayed SM; Elzahhar PA; Moustafa MA
    Bioorg Chem; 2023 Dec; 141():106874. PubMed ID: 37769524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers.
    Elmetwally SA; Saied KF; Eissa IH; Elkaeed EB
    Bioorg Chem; 2019 Jul; 88():102944. PubMed ID: 31051400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dihydrofolate reductase inhibition effect of 5-substituted pyrido[2,3-d]pyrimidines: Synthesis, antitumor activity and molecular modeling study.
    Abdelaziz OA; El Husseiny WM; Selim KB; Eisa HM
    Bioorg Chem; 2019 Sep; 90():103076. PubMed ID: 31260878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers.
    Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M
    Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells.
    Farghaly AM; AboulWafa OM; Baghdadi HH; Abd El Razik HA; Sedra SMY; Shamaa MM
    Bioorg Chem; 2021 Oct; 115():105208. PubMed ID: 34365057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological evaluation of imidazo[2,1-b]thiazole-benzimidazole conjugates as microtubule-targeting agents.
    Baig MF; Nayak VL; Budaganaboyina P; Mullagiri K; Sunkari S; Gour J; Kamal A
    Bioorg Chem; 2018 Apr; 77():515-526. PubMed ID: 29459129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyrazolo[3,4-d]pyrimidine-based dual EGFR T790M/HER2 inhibitors: Design, synthesis, structure-activity relationship and biological activity as potential antitumor and anticonvulsant agents.
    Lamie PF; El-Kalaawy AM; Abdel Latif NS; Rashed LA; Philoppes JN
    Eur J Med Chem; 2021 Mar; 214():113222. PubMed ID: 33545637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis, cytotoxic evaluation, and molecular docking studies of novel quinazoline derivatives with benzenesulfonamide and anilide tails: Dual inhibitors of EGFR/HER2.
    Alkahtani HM; Abdalla AN; Obaidullah AJ; Alanazi MM; Almehizia AA; Alanazi MG; Ahmed AY; Alwassil OI; Darwish HW; Abdel-Aziz AA; El-Azab AS
    Bioorg Chem; 2020 Jan; 95():103461. PubMed ID: 31838290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.